

FAECAL MICROBIOTA SIGNATURE FOR PANCREATIC CANCER

The CNIO has developed a method for early detection of pancreatic cancer.

Industrial partners are being sought to collaborate through a patent license agreement for the development and exploitation of the technology.

Description

The inventors have found a method for early diagnosing pancreatic cancer based on a faecal microbiota signature with high specificity for pancreatic cancer.

Main innovations and advantages

The method of the invention is a sensitive, specific and non-invasive method for an early detection of pancreatic cancer, in particular Pancreatic Ductal Adenocarcinoma (PDAC) that could therefore improve survival outcomes.

The present invention refers to a method for diagnosing pancreatic cancer in a subject comprising determining the abundance of several Microbiome species in a faecal sample from said subject, as well as to a kit and its use for the diagnosis of pancreatic cancer.

Intellectual property

Patent title:

FAECAL MICROBIOTA SIGNATURE FOR PANCREATIC CANCER

Applicants:

Spanish National Cancer Research Center (CNIO) and European Molecular Biology Laboratory (EMBL)

International patent application:

WO2023/052486 (A1)

Patent application suitable for entering national/regional phase

For more information, please contact:

Technology Transfer and Valorization Office
Centro Nacional de Investigaciones Oncológicas
C/ Melchor Fernández Almagro, 3. 28029 Madrid
Spain

technologytransfer@cnio.es

www.cnio.es

@CNIO_Cancer



cnio stop cancer

BECOME A
CNIO FRIEND

EMBL RESEARCH
LESS CANCER